Abstract
Summary
Nonalcoholic steatohepatitis is a syndrome causes liver damage develops in the individuals who are not alcoholic. The primary mechanisms of nonalcoholic steatohepatitis are obesity, glucose intolerance, metabolic stress, inflammation, dyslipidemia and fibrosis. Nonalcoholic steatohepatitis can develop into cirrhosis and liver cancer. For the diagnosis of the nonalcoholic steatohepatitis, liver biopsy, imaging procedures and various types of blood tests including complete blood count, fasting blood sugar, liver enzyme tests etc. are required. The common nonalcoholic steatohepatitis treatment may include weight loss, type-2 diabetes treatment, a decrease of obesity etc. However, many drugs have been tested for the nonalcoholic steatohepatitis treatment only a few drugs such as vitamin E and pioglitazone showed a positive effect. Other drugs such as ursodeoxycholic acid, metformin, statins, orlistat and pentoxifylline showed only partially positive results.The major elements that can be considered for the pathological protagonists of nonalcoholic steatohepatitis are oxidative stress, altered lipid metabolism adipose and pancreas tissues, bile acids, gut microbiota, bacterial endotoxins, and systemic chronic inflammation.
LPI (LP Information)' newest research report, the “Nonalcoholic Steatohepatitis Treatment Industry Forecast” looks at past sales and reviews total world Nonalcoholic Steatohepatitis Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Nonalcoholic Steatohepatitis Treatment sales for 2023 through 2029. With Nonalcoholic Steatohepatitis Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nonalcoholic Steatohepatitis Treatment industry.
This Insight Report provides a comprehensive analysis of the global Nonalcoholic Steatohepatitis Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nonalcoholic Steatohepatitis Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Nonalcoholic Steatohepatitis Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nonalcoholic Steatohepatitis Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nonalcoholic Steatohepatitis Treatment.
The global Nonalcoholic Steatohepatitis Treatment market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Nonalcoholic Steatohepatitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Nonalcoholic Steatohepatitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Nonalcoholic Steatohepatitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Nonalcoholic Steatohepatitis Treatment players cover AstraZeneca, Arena Pharmaceuticals, GSK, Novo Nordisk, Roche, Vivus, Arisaph Pharmaceuticals, Cempra Pharmaceuticals and Galectin Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Nonalcoholic Steatohepatitis Treatment market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Solid
Liquid
Segmentation by application
Hospital
Diagnostic Center
Specialized Clinic
Hospital Pharmacy
Drug Store
Mail Order Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Arena Pharmaceuticals
GSK
Novo Nordisk
Roche
Vivus
Arisaph Pharmaceuticals
Cempra Pharmaceuticals
Galectin Therapeutics
Galmed Pharmaceuticals
Genfit
Gilead
Key Questions Addressed in this Report
What is the 10-year outlook for the global Nonalcoholic Steatohepatitis Treatment market?
What factors are driving Nonalcoholic Steatohepatitis Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Nonalcoholic Steatohepatitis Treatment market opportunities vary by end market size?
How does Nonalcoholic Steatohepatitis Treatment break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Nonalcoholic Steatohepatitis Treatment Industry Forecast” looks at past sales and reviews total world Nonalcoholic Steatohepatitis Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Nonalcoholic Steatohepatitis Treatment sales for 2023 through 2029. With Nonalcoholic Steatohepatitis Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nonalcoholic Steatohepatitis Treatment industry.
This Insight Report provides a comprehensive analysis of the global Nonalcoholic Steatohepatitis Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nonalcoholic Steatohepatitis Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Nonalcoholic Steatohepatitis Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nonalcoholic Steatohepatitis Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nonalcoholic Steatohepatitis Treatment.
The global Nonalcoholic Steatohepatitis Treatment market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Nonalcoholic Steatohepatitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Nonalcoholic Steatohepatitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Nonalcoholic Steatohepatitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Nonalcoholic Steatohepatitis Treatment players cover AstraZeneca, Arena Pharmaceuticals, GSK, Novo Nordisk, Roche, Vivus, Arisaph Pharmaceuticals, Cempra Pharmaceuticals and Galectin Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Nonalcoholic Steatohepatitis Treatment market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Solid
Liquid
Segmentation by application
Hospital
Diagnostic Center
Specialized Clinic
Hospital Pharmacy
Drug Store
Mail Order Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Arena Pharmaceuticals
GSK
Novo Nordisk
Roche
Vivus
Arisaph Pharmaceuticals
Cempra Pharmaceuticals
Galectin Therapeutics
Galmed Pharmaceuticals
Genfit
Gilead
Key Questions Addressed in this Report
What is the 10-year outlook for the global Nonalcoholic Steatohepatitis Treatment market?
What factors are driving Nonalcoholic Steatohepatitis Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Nonalcoholic Steatohepatitis Treatment market opportunities vary by end market size?
How does Nonalcoholic Steatohepatitis Treatment break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Nonalcoholic Steatohepatitis Treatment Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Nonalcoholic Steatohepatitis Treatment by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Nonalcoholic Steatohepatitis Treatment by Country/Region, 2018, 2022 & 2029
2.2 Nonalcoholic Steatohepatitis Treatment Segment by Type
2.2.1 Solid
2.2.2 Liquid
2.3 Nonalcoholic Steatohepatitis Treatment Sales by Type
2.3.1 Global Nonalcoholic Steatohepatitis Treatment Sales Market Share by Type (2018-2023)
2.3.2 Global Nonalcoholic Steatohepatitis Treatment Revenue and Market Share by Type (2018-2023)
2.3.3 Global Nonalcoholic Steatohepatitis Treatment Sale Price by Type (2018-2023)
2.4 Nonalcoholic Steatohepatitis Treatment Segment by Application
2.4.1 Hospital
2.4.2 Diagnostic Center
2.4.3 Specialized Clinic
2.4.4 Hospital Pharmacy
2.4.5 Drug Store
2.4.6 Mail Order Pharmacy
2.5 Nonalcoholic Steatohepatitis Treatment Sales by Application
2.5.1 Global Nonalcoholic Steatohepatitis Treatment Sale Market Share by Application (2018-2023)
2.5.2 Global Nonalcoholic Steatohepatitis Treatment Revenue and Market Share by Application (2018-2023)
2.5.3 Global Nonalcoholic Steatohepatitis Treatment Sale Price by Application (2018-2023)
3 Global Nonalcoholic Steatohepatitis Treatment by Company
3.1 Global Nonalcoholic Steatohepatitis Treatment Breakdown Data by Company
3.1.1 Global Nonalcoholic Steatohepatitis Treatment Annual Sales by Company (2018-2023)
3.1.2 Global Nonalcoholic Steatohepatitis Treatment Sales Market Share by Company (2018-2023)
3.2 Global Nonalcoholic Steatohepatitis Treatment Annual Revenue by Company (2018-2023)
3.2.1 Global Nonalcoholic Steatohepatitis Treatment Revenue by Company (2018-2023)
3.2.2 Global Nonalcoholic Steatohepatitis Treatment Revenue Market Share by Company (2018-2023)
3.3 Global Nonalcoholic Steatohepatitis Treatment Sale Price by Company
3.4 Key Manufacturers Nonalcoholic Steatohepatitis Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Nonalcoholic Steatohepatitis Treatment Product Location Distribution
3.4.2 Players Nonalcoholic Steatohepatitis Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Nonalcoholic Steatohepatitis Treatment by Geographic Region
4.1 World Historic Nonalcoholic Steatohepatitis Treatment Market Size by Geographic Region (2018-2023)
4.1.1 Global Nonalcoholic Steatohepatitis Treatment Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Nonalcoholic Steatohepatitis Treatment Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Nonalcoholic Steatohepatitis Treatment Market Size by Country/Region (2018-2023)
4.2.1 Global Nonalcoholic Steatohepatitis Treatment Annual Sales by Country/Region (2018-2023)
4.2.2 Global Nonalcoholic Steatohepatitis Treatment Annual Revenue by Country/Region (2018-2023)
4.3 Americas Nonalcoholic Steatohepatitis Treatment Sales Growth
4.4 APAC Nonalcoholic Steatohepatitis Treatment Sales Growth
4.5 Europe Nonalcoholic Steatohepatitis Treatment Sales Growth
4.6 Middle East & Africa Nonalcoholic Steatohepatitis Treatment Sales Growth
5 Americas
5.1 Americas Nonalcoholic Steatohepatitis Treatment Sales by Country
5.1.1 Americas Nonalcoholic Steatohepatitis Treatment Sales by Country (2018-2023)
5.1.2 Americas Nonalcoholic Steatohepatitis Treatment Revenue by Country (2018-2023)
5.2 Americas Nonalcoholic Steatohepatitis Treatment Sales by Type
5.3 Americas Nonalcoholic Steatohepatitis Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Nonalcoholic Steatohepatitis Treatment Sales by Region
6.1.1 APAC Nonalcoholic Steatohepatitis Treatment Sales by Region (2018-2023)
6.1.2 APAC Nonalcoholic Steatohepatitis Treatment Revenue by Region (2018-2023)
6.2 APAC Nonalcoholic Steatohepatitis Treatment Sales by Type
6.3 APAC Nonalcoholic Steatohepatitis Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Nonalcoholic Steatohepatitis Treatment by Country
7.1.1 Europe Nonalcoholic Steatohepatitis Treatment Sales by Country (2018-2023)
7.1.2 Europe Nonalcoholic Steatohepatitis Treatment Revenue by Country (2018-2023)
7.2 Europe Nonalcoholic Steatohepatitis Treatment Sales by Type
7.3 Europe Nonalcoholic Steatohepatitis Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Nonalcoholic Steatohepatitis Treatment by Country
8.1.1 Middle East & Africa Nonalcoholic Steatohepatitis Treatment Sales by Country (2018-2023)
8.1.2 Middle East & Africa Nonalcoholic Steatohepatitis Treatment Revenue by Country (2018-2023)
8.2 Middle East & Africa Nonalcoholic Steatohepatitis Treatment Sales by Type
8.3 Middle East & Africa Nonalcoholic Steatohepatitis Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Nonalcoholic Steatohepatitis Treatment
10.3 Manufacturing Process Analysis of Nonalcoholic Steatohepatitis Treatment
10.4 Industry Chain Structure of Nonalcoholic Steatohepatitis Treatment
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Nonalcoholic Steatohepatitis Treatment Distributors
11.3 Nonalcoholic Steatohepatitis Treatment Customer
12 World Forecast Review for Nonalcoholic Steatohepatitis Treatment by Geographic Region
12.1 Global Nonalcoholic Steatohepatitis Treatment Market Size Forecast by Region
12.1.1 Global Nonalcoholic Steatohepatitis Treatment Forecast by Region (2024-2029)
12.1.2 Global Nonalcoholic Steatohepatitis Treatment Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Nonalcoholic Steatohepatitis Treatment Forecast by Type
12.7 Global Nonalcoholic Steatohepatitis Treatment Forecast by Application
13 Key Players Analysis
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Nonalcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.1.3 AstraZeneca Nonalcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 Arena Pharmaceuticals
13.2.1 Arena Pharmaceuticals Company Information
13.2.2 Arena Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.2.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Arena Pharmaceuticals Main Business Overview
13.2.5 Arena Pharmaceuticals Latest Developments
13.3 GSK
13.3.1 GSK Company Information
13.3.2 GSK Nonalcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.3.3 GSK Nonalcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 GSK Main Business Overview
13.3.5 GSK Latest Developments
13.4 Novo Nordisk
13.4.1 Novo Nordisk Company Information
13.4.2 Novo Nordisk Nonalcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.4.3 Novo Nordisk Nonalcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novo Nordisk Main Business Overview
13.4.5 Novo Nordisk Latest Developments
13.5 Roche
13.5.1 Roche Company Information
13.5.2 Roche Nonalcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.5.3 Roche Nonalcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Roche Main Business Overview
13.5.5 Roche Latest Developments
13.6 Vivus
13.6.1 Vivus Company Information
13.6.2 Vivus Nonalcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.6.3 Vivus Nonalcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Vivus Main Business Overview
13.6.5 Vivus Latest Developments
13.7 Arisaph Pharmaceuticals
13.7.1 Arisaph Pharmaceuticals Company Information
13.7.2 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.7.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Arisaph Pharmaceuticals Main Business Overview
13.7.5 Arisaph Pharmaceuticals Latest Developments
13.8 Cempra Pharmaceuticals
13.8.1 Cempra Pharmaceuticals Company Information
13.8.2 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.8.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Cempra Pharmaceuticals Main Business Overview
13.8.5 Cempra Pharmaceuticals Latest Developments
13.9 Galectin Therapeutics
13.9.1 Galectin Therapeutics Company Information
13.9.2 Galectin Therapeutics Nonalcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.9.3 Galectin Therapeutics Nonalcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Galectin Therapeutics Main Business Overview
13.9.5 Galectin Therapeutics Latest Developments
13.10 Galmed Pharmaceuticals
13.10.1 Galmed Pharmaceuticals Company Information
13.10.2 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Galmed Pharmaceuticals Main Business Overview
13.10.5 Galmed Pharmaceuticals Latest Developments
13.11 Genfit
13.11.1 Genfit Company Information
13.11.2 Genfit Nonalcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.11.3 Genfit Nonalcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Genfit Main Business Overview
13.11.5 Genfit Latest Developments
13.12 Gilead
13.12.1 Gilead Company Information
13.12.2 Gilead Nonalcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.12.3 Gilead Nonalcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Gilead Main Business Overview
13.12.5 Gilead Latest Developments
14 Research Findings and Conclusion